Microbial Clearance of Refractory Mycobacterium avium Complex Pulmonary Disease During Pembrolizumab and Intensified Antimicrobial Therapy: A Case Report
Abstract
1. Introduction
2. Case Presentation
3. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Griffith, D.E.; Brown-Elliott, B.A.; Langsjoen, B.; Zhang, Y. Clinical and molecular analysis of macrolide resistance in complex lung disease. Am. J. Respir. Crit. Care Med. 2006, 174, 928–934. [Google Scholar] [CrossRef] [PubMed]
- Park, Y.; Lee, E.H.; Jung, I.; Park, G.; Kang, Y.A. Clinical characteristics and treatment outcomes of patients with macrolide-resistant complex pulmonary disease: A systematic review and meta-analysis. Respir. Res. 2019, 20, 286. [Google Scholar] [CrossRef]
- Ito, Y.; Miwa, S.; Shirai, M.; Kanai, M.; Fujita, K.; Ohba, H.; Iwaizumi, E.; Oshima, T.; Kojima, S.; Suda, T.; et al. Macrolide resistant complex pulmonary disease following clarithromycin and ethambutol combination therapy. Respir. Med. 2020, 169, 106025. [Google Scholar] [CrossRef]
- Kumar, K.; Daley, C.L.; Griffith, D.E.; Loebinger, M.R. Management of complex and pulmonary disease: Therapeutic advances and emerging treatments. Eur. Respir. Rev. 2022, 31, 210212. [Google Scholar] [CrossRef] [PubMed]
- Brown-Elliott, B.A.; Philley, J.V.; Griffith, D.E.; Thakkar, F.; Wallace, R.J., Jr. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex. Antimicrob. Agents Chemother. 2017, 61, e01798-16. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Han, Y.; Liu, D.; Li, L. PD-1/PD-L1 pathway: Current researches in cancer. Am. J. Cancer Res. 2020, 10, 727–742. [Google Scholar] [PubMed] [PubMed Central]
- Pardoll, D. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12, 252–264. [Google Scholar] [CrossRef]
- André, T.; Shiu, K.K.; Kim, T.W.; Jensen, B.V.; Jensen, L.H.; Punt, C.; Smith, D.; Garcia-Carbonero, R.; Benavides, M.; Gibbs, P.; et al. KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N. Engl. J. Med. 2020, 383, 2207–2218. [Google Scholar] [CrossRef] [PubMed]
- Corti, M.; Palmero, D. Mycobacterium avium complex infection in HIV/AIDS patients. Expert. Rev. Anti-Infect. Ther. 2008, 6, 351–363. [Google Scholar] [CrossRef] [PubMed]
- von Grünberg, P.W.; Plum, G. Enhanced induction of interleukin-12(p40) secretion by human macrophages infected with Mycobacterium avium complex isolates from disseminated infection in AIDS patients. J. Infect. Dis. 1998, 178, 1209–1212. [Google Scholar] [CrossRef] [PubMed]
- Hartmann, P.; Plum, G. Immunological defense mechanisms in tuberculosis and mac-infection. Diagn. Microbiol. Infect. Dis. 1999, 34, 147–152. [Google Scholar] [CrossRef] [PubMed]
- Moguche, A.O.; Musvosvi, M.; Penn-Nicholson, A.; Plumlee, C.R.; Mearns, H.; Geldenhuys, H.; Smit, E.; Abrahams, D.; Rozot, V.; Dintwe, O.; et al. Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. Cell Host Microbe 2017, 21, 695–706.e5. [Google Scholar] [CrossRef]
- Kathrin Lösslein, A.; Henneke, P. Mycobacterial immunevasion—Spotlight on the enemy within. J. Leukoc. Biol. 2021, 109, 9–11. [Google Scholar] [CrossRef] [PubMed]
- Shu, C.-C.; Wang, J.-Y.; Wu, M.-F.; Lai, H.-C.; Chiang, B.-L.; Yu, C.-J. Interleukin 23/interleukin 17 axis activated by Mycobacterium avium complex (MAC) is attenuated in patients with MAC-lung disease. Tuberculosis 2018, 110, 7–14. [Google Scholar] [CrossRef]
- Tezera, L.B.; Bielecka, M.K.; Ogongo, P.; Walker, N.F.; Ellis, M.; Garay-Baquero, D.J.; Thomas, K.; Reichmann, M.T.; A Johnston, D.; Wilkinson, K.A.; et al. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. eLife 2020, 9, 52668. [Google Scholar] [CrossRef] [PubMed]
- Mejia-Chew, C.; Spec, A.; Walton, A.H.; Antonova, A.U.; Dram, A.; Bhalla, S.; Colonna, M.; Morre, M.; Hotchkiss, R. Recombinant interleukin-7 treatment of refractory Mycobacterium avium complex lung disease (IMPULSE-7): A pilot phase II, single-center, randomized, clinical trial. Ther. Adv. Infect. Dis. 2025, 12, 20499361251339300. [Google Scholar] [CrossRef]
- Lin, S.; Hua, W.; Wang, S.; Zhang, Y.; Chen, X.; Liu, H.; Shao, L.; Chen, J.; Zhang, W. In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates. BMC Microbiol. 2022, 22, 175. [Google Scholar] [CrossRef]
- Ruth, M.M.; Sangen, J.J.N.; Remmers, K.; Pennings, L.J.; Svensson, E.; E Aarnoutse, R.; Zweijpfenning, S.M.H.; Hoefsloot, W.; Kuipers, S.; Magis-Escurra, C.; et al. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J. Antimicrob. Chemother. 2019, 74, 935–943. [Google Scholar] [CrossRef]
- Karlowsky, J.A.; Steenbergen, J.; Zhanel, G.G. Microbiology and Preclinical Review of Omadacycline. Clin Infect Dis. 2019, 69 (Suppl. 1), S6–S15. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kuksa, L.; Andrejak, C.; Haecker, B.; Bothamley, G.; Calcagno, A.; Cirillo, D.M.; Duarte, R.; Fatima, R.; Ferlazzo, G.; Guglielmetti, L.; et al. Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy. IJTLD Open 2025, 2, 117–119. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Anastasopoulou, A.; Ziogas, D.C.; Samarkos, M.; Kirkwood, J.M.; Gogas, H. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: Current evidence and clinical practice recommendations. J. Immunother. Cancer 2019, 7, 239. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Langan, E.A.; Graetz, V.; Allerheiligen, J.; Zillikens, D.; Rupp, J.; Terheyden, P. Immune checkpoint inhibitors and tuberculosis: An old disease in a new context. Lancet Oncol. 2020, 21, e55–e65. [Google Scholar] [CrossRef] [PubMed]
Antimicrobial Agent/Test | Feb 2015 | Aug 2016 | Jun 2021 | Jan 2022 | Oct 2022 | May 2023 |
---|---|---|---|---|---|---|
Amikacin | 4 (S) | 16 (S) | 32 (I) | 32 (I) | 16 (S) | — |
Clarithromycin | 2 (S) | 2 (S) | >64 (R) | >64 (R) | >64 (R) | — |
Linezolid | 16 (I) | 16 (I) | 16 (I) | 16 (I) | 16 (I) | — |
Moxifloxacin | 2 (I) | 4 (R) | 4 (R) | 4 (R) | >4 (R) | — |
Rifabutin | ≤0.25 (NI) | ≤0.25 (NI) | — | — | 2 | — |
Ethambutol | ≤0.5 (NI) | 16 (NI) | — | — | — | — |
Streptomycin | — | — | 64 (NI) | — | >32 | — |
Omadacycline | — | — | — | — | >8 | — |
Bedaquiline | — | — | — | — | 0.004 | — |
Tedizolid | — | — | — | — | 4 | — |
Ciprofloxacin | — | — | — | — | >8 | — |
Doxycycline | — | — | — | — | >8 | — |
Minocycline | — | — | — | — | >8 | — |
Rifampin | — | — | — | — | >4 | — |
Trimethoprim /Sulfamethoxazole | — | — | — | — | 2/38 | — |
AFB Culture | MAC isolated | MAC isolated | MAC isolated | MAC isolated | MAC isolated | Negative |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kaur, J.N.; Padhi, P.; Pal, S. Microbial Clearance of Refractory Mycobacterium avium Complex Pulmonary Disease During Pembrolizumab and Intensified Antimicrobial Therapy: A Case Report. Pharmaceuticals 2025, 18, 1464. https://doi.org/10.3390/ph18101464
Kaur JN, Padhi P, Pal S. Microbial Clearance of Refractory Mycobacterium avium Complex Pulmonary Disease During Pembrolizumab and Intensified Antimicrobial Therapy: A Case Report. Pharmaceuticals. 2025; 18(10):1464. https://doi.org/10.3390/ph18101464
Chicago/Turabian StyleKaur, Jan Naseer, Parikshit Padhi, and Suhani Pal. 2025. "Microbial Clearance of Refractory Mycobacterium avium Complex Pulmonary Disease During Pembrolizumab and Intensified Antimicrobial Therapy: A Case Report" Pharmaceuticals 18, no. 10: 1464. https://doi.org/10.3390/ph18101464
APA StyleKaur, J. N., Padhi, P., & Pal, S. (2025). Microbial Clearance of Refractory Mycobacterium avium Complex Pulmonary Disease During Pembrolizumab and Intensified Antimicrobial Therapy: A Case Report. Pharmaceuticals, 18(10), 1464. https://doi.org/10.3390/ph18101464